Skip to main content
editorial
. 2024 Aug 26;9(8):968–970. doi: 10.1016/j.jacbts.2024.06.002

Figure 1.

Figure 1

CH Predicts Adverse Cardiac Remodeling

Clonal hematopoiesis (CH) driver mutations increase myocardial inflammation via macrophage inflammasome, interleukin-1, and interleukin-6 expression. Patients with dilated cardiomyopathy (DCM) and CH have a lower chance of reverse cardiac remodeling, independent of germline mutation in DCM-associated genes. Immunomodulatory therapy may ultimately improve cardiac remodeling in DCM.